
  Mrv0541 04191212142D          

 10 10  0  0  0  0            999 V2000
   -0.7500    1.1375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4645    0.7250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4645   -0.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0355    0.7250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7500   -0.5125    0.0000 N   0  3  0  0  0  0  0  0  0  0  0  0
   -0.7500   -1.3375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0355   -0.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6789   -0.5125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3934   -0.1000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1079   -0.5125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  1  4  2  0  0  0  0
  2  3  2  0  0  0  0
  3  5  1  0  0  0  0
  5  7  2  0  0  0  0
  7  4  1  0  0  0  0
  5  6  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
M  END
> <DRUGBANK_ID>
DB00733

> <DRUG_GROUPS>
approved

> <GENERIC_NAME>
Pralidoxime

> <SYNONYMS>
2-PAM; Pralidoxim; Pralidoxima; Pralidoxime; Pralidoximum

> <SALTS>
Pralidoxime Chloride

> <BRANDS>
Contrathion; Nispam; Pamcl; Pampara; Pamu; Pralidoxime Chloride; Protopam; Protopam Chloride

> <CHEMICAL_FORMULA>
C7H9N2O

> <MOLECULAR_WEIGHT>
137.1592

> <EXACT_MASS>
137.07148792

> <IUPAC_NAME>
2-[(1E)-(hydroxyimino)methyl]-1-methylpyridin-1-ium

> <IUPAC_TRADITIONAL_NAME>
pralidoxime

> <INCHI_IDENTIFIER>
InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1

> <INCHI_KEY>
InChIKey=JBKPUQTUERUYQE-UHFFFAOYSA-O

> <SMILES>
C[N+]1=C(\C=N\O)C=CC=C1

> <JCHEM_ACCEPTOR_COUNT>
2

> <JCHEM_DONOR_COUNT>
1

> <JCHEM_ACIDIC_PKA>
5.78

> <JCHEM_BASIC_PKA>
-1.1

> <JCHEM_PHYSIOLOGICAL_CHARGE>
0

> <ALOGPS_LOGP>
-3

> <JCHEM_LOGP>
-3.3

> <ALOGPS_LOGS>
-3.1

> <JCHEM_POLARIZABILITY>
14.44

> <JCHEM_POLAR_SURFACE_AREA>
36.47

> <JCHEM_REFRACTIVITY>
40.33

> <JCHEM_ROTATABLE_BOND_COUNT>
1

> <ALOGPS_SOLUBILITY>
1.49e-01 g/l __ 

$$$$
